<DOC>
	<DOCNO>NCT00885352</DOCNO>
	<brief_summary>This study examine safety efficacy addition sitagliptin ( MK-0431 ) compare placebo patient type 2 diabetes mellitus inadequate glycemic control take pioglitazone metformin .</brief_summary>
	<brief_title>Sitagliptin ( MK-0431 ) v . Placebo Patients With Inadequate Glycemic Control Metformin With Pioglitazone ( MK-0431-128 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>type 2 diabetes least 18 year age old 78 year age male female unlikely conceive child stable dos peroxisome proliferatoractivated receptor gamma agonist metformin OR metformin sulfonylurea agent type 1 diabetes take dipeptidyl peptidase ( DPP4 ) inhibitor glucagonlike peptide1 ( GLP1 ) analogue weight loss program maintenance phase start weight loss medication within 8 week screen surgery within 30 day screen major surgery plan study likely require treatment corticosteroid 2 week history active liver disease , include hepatitis B C , cirrhosis , gallbladder disease human immunodeficiency virus ( HIV ) positive congestive heart failure , new worsen symptom coronary heart disease within 3 month prior screen acute coronary syndrome , coronary artery intervention , stroke within 3 month screen severe active peripheral vascular disease history cancer blood disorder pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>